Speech evaluation with the clinical evaluation of dysarthria
OtherA first speech evaluation with the clinical evaluation of dysarthria during 30 minutes is proposed to exclude very severe dysarthria.
NCT Number: NCT04630574
The study proposes to identify deviant speech dimensions in patients with HD at presymptomatic and declared stages of the disease, compared to healthy subjects, using the computerized MonPaGe speech protocol. This tool is based on a multidimensional and quantified assessment of voice and speech, by a set of targeted acoustic and perceptual criteria.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Hôpital Henri-Mondor, Créteil, France
Huntington's disease (HD) is a neurodegenerative disorder of the central nervous system, of genetic etiology. It manifests itself in motor, cognitive and psychiatric disorders, which progressively worsen until the patient is grabbed. Motor speech performance disorders are present from the early stage of the disease. These difficulties, which progressively worsen until the end of the patient's life, lead to a communication disorder and constitute a major handicap with social withdrawal, loss of self-esteem and isolation, which are always very painfully experienced by patients and their entourage. Dysarthria in the HD has been very little studied, which makes its speech therapy uncodified. According to the most widely used classification by speech therapists and neurologists, the Darley classification (1975), the speech disorders observed in the HD are included in the heterogeneous group of hyperkinetic dysarthria, whose contours and properties are ill-defined. In this context, a more precise knowledge of speech disorders in the HD appears necessary to identify and characterize the different types of dysarthria and the dysfunctions associated with each level of production (respiration, phonation, resonance, articulation, prosody) and thus improve speech language therapy.
The investigators propose to use an acoustic evaluation to support the perceptual evaluation, available in the MonPaGe protocol, to describe the fine characteristics of the speech disorders in the HD and to define objective markers of dysarthria in this disease for francophone patients.
Each patient is seen in the framework of his annual follow-up consultation in the Competence Center mdH of Bordeaux University Hospital or in the Reference Center mdH of the hospital Henri Mondor of Créteil, for an evaluation of his speech with the computerized tool MonPaGe. A first speech evaluation with the BECD (Auzou, 2006) during 30 minutes is proposed to exclude very severe dysarthria. At the end of this rapid test subtest, the subjects who obtain a perceptive score <16 are offered the complete assesment of the MonPaGe computerized protocol (30 minutes).The application records directly and anonymously stores speech productions made by the patient.The productions are transmitted to the Phonetics and Phonology Laboratory of Paris (UMR 7018 CNRS / Sorbonne Nouvelle), via a secure large data exchange server and are subject to a perceptual and acoustic evaluation a posteriori.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A first speech evaluation with the clinical evaluation of dysarthria during 30 minutes is proposed to exclude very severe dysarthria.
The application records directly and anonymously stores speech productions made by the patient.
Time frame: Day 1
Defined as the number of words correctly recognized by the evaluator (score out of 15).
Time frame: Day 1
Expressed in milliseconds.
Time frame: Day 1
Described as the mean and standard deviation of fundamental frequency (in Hz),
Time frame: Day 1
Based on a scale of 0 to 4.
Time frame: Day 1
Expressed in Hz. Extracted from the spectral properties of the acoustic signal of certain words.
Time frame: Day 1
assessed on a scale 0 to 4 on particular sentences.
Time frame: Day 1
assessed on two scales: precision (0 to 4) and control (0 to 4).
Time frame: Day 1
expressed in syllabs per second.
Time frame: Day 1
The Huntington's disease stage will be determined based on the Total Functional Capacity (TFC) and the Total Motor Score (TMS) scales of the Unified Huntington's Disease Rating Scale:
Time frame: Day 1
The clinical motor forms of Huntington disease will be determined by the motor UHDRS scale (Total Motor Score), which evaluates oculomotricity, skill and manual planning, bradykinesia, dystonia and rigidity, chorea and walking, balance, lingual protrusion and dysarthria.
Time frame: Day 1
The level of cognitive impairment will be assessed by the cognitive score as per the Unified Huntington's Disease Rating Scale.
University Hospital, Bordeaux
Other
Acronym: TPMH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06667414
Basal Ganglia Diseases, Brain Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT05157074
Basal Ganglia Diseases, Behavior
Baltimore, Maryland, United States
View Trial DetailsNCT00465790
Autonomic Nervous System Diseases, Basal Ganglia Diseases
Split, Croatia
View Trial DetailsNCT05358717
Basal Ganglia Diseases, Brain Diseases
La Jolla, California, United States
View Trial Details